Biomarin Pharmaceutical Inc
BMRN.OQ- Latest Trade
- trading lower85.35USD
- Change
- -1.5
- % Change
1.73%Negative
- Day Range
- 84.63 - 86.71
- 52-Week Range
- 70.76 - 94.18
As of Jun 27 2022. Values delayed up to 15 minutes
- Previous Close
- 86.85
- Open
- 86.37
- Volume
- 198,633.00
- 3 Month Average Trading Volume
- 26.36
- Shares Out (Mil)
- 185.00
- Market Cap
- 16,066.85
- Forward P/E
- 109.59
- Dividend Yield
- -99,999.99
Key Statistics
1.76190476 mean rating - 21 analysts
- P/E Excl. Extra Items (TTM)
- 565.17
- Price To Sales (TTM)
- 8.55
- Price To Book (Quarterly)
- 3.66
- Price To Cash Flow (Per Share TTM)
- 112.50
- Total Debt/Total Equity (Quarterly)
- 24.60
- Long Term Debt/Equity (Quarterly)
- 24.60
- Return On Investment (TTM)
- 0.65
- Return On Equity (TTM)
- 0.60
2021 (millions USD)
About Biomarin Pharmaceutical Inc
Company Information
BioMarin Pharmaceutical Inc. (BioMarin) is a biotechnology company that develops and commercializes therapies. The Company's portfolio consists of seven commercial products and multiple clinical and preclinical product candidates for the treatment of various diseases. BioMarin 's commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa) and Voxzogo (vosoritide). BioMarin's clinical development programs include Valoctocogene roxaparvovec is an adeno associated virus (AAV5) vector drug development candidate designed to restore factor VIII plasma concentrations in patients with severe hemophilia A; BMN 307 is an AAV5 mediated gene therapy that is designed to normalize blood Phe concentration levels in patients with Phenylketonuria (PKU), and BMN 255 is a small-molecule therapy that is designed to treat primary hyperoxaluria type 1, a subset of chronic renal disease.
Address
105 Digital DrNOVATO, CA
94949-8703
United States
Industry
Biotechnology & Drugs
Executive Leadership
- Jean-Jacques Bienaime
- Chairman of the Board, Chief Executive Officer
- Brian R. Mueller
- Chief Financial Officer, Executive Vice President - Finance
- Henry J. Fuchs
- President - Worldwide Research and Development
- C. Greg Guyer
- Executive Vice President - Global Manufacturing and Technical Operations, Chief Technical Officer
- G. Eric Davis
- Executive Vice President, General Counsel, Secretary
- Jeff Robert Ajer
- Executive Vice President, Chief Commercial Officer
- Humaira Serajuddin
- Senior Vice President, Chief Marketing Officer
- Erin Burkhart
- Group Vice President, Chief Accounting Officer
- Richard A. Meier
- Lead Independent Director
- Mark J. Alles
- Independent Director
- Elizabeth McKey Anderson
- Independent Director
- Willard H. Dere
- Independent Director
- Elaine J. Heron
- Independent Director
- Maykin Ho
- Independent Director
- Robert J. Hombach
- Independent Director
- V. Bryan Lawlis
- Independent Director
- David E. I. Pyott
- Independent Director
- Dennis J. Slamon
- Independent Director
Markets Performance
Official Data PartnerCommodities
| Future | Last | % Change |
|---|---|---|
| Gold | 1,822.90 | 0.20%Negative |
| Copper | 700.00 | 1.18%Positive |
| Brent Crude Oil | 114.60 | 1.31%Positive |
| CBOT Soybeans | 1,629.50 | 1.16%Positive |
Stocks
| Index | Last | % Change |
|---|---|---|
| S&P 500 | 3,923.13 | 0.29%Positive |
| Euro STOXX 50 | 3,547.65 | 0.41%Positive |
| FTSE 100 | 7,258.32 | 0.69%Positive |
| Nikkei 225 | 26,871.27 | 1.43%Positive |
Source: Refinitiv, an LSEG business - data delayed by at least 15 minutes